This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Current immunotherapies have helped many patients with advanced tumors, but some experts think that the odds of success would likely improve if we could treat tumors before they’ve progressed to late stages. However, more must first be known about cancer and immune cell interactions throughout tumor development, so Dr. Cong is creating a mouse model of lung cancer to analyze individual cells over time. Then, he plans to use computational modeling to compare and validate these findings with human tumor samples. This may allow Dr. Cong to identify key “druggable” events that could be targeted during tumor development and enhance immunotherapy’s effectiveness in patients.
Broad Institute of MIT and Harvard | All Cancers, Lung Cancer | 2016 | Aviv Regev, Ph.D.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Meet three promising young scientists changing the face of immuno-oncology: Ryan K. Alexander, Ph.D., of Boston Children’s Hospital; Nelson M. LaMarche, Ph.D., of the Icahn School of Medicine at Mount Sinai; and Christopher B. Medina, Ph.D., of Emory University.
New research, new treatments, and how we’re working toward a future immune to cervical cancer